100 results about "(R)-lipoic acid" patented technology

A topical composition comprising a lipoic acid, a carnitine, and a carnosine in a suitable vehicle for topical application and a method for treating skin is provided. The present compositions are useful in improving the appearance of aged skin characterized by wrinkles and loss of elasticity. Preferred components include R-lipoic acid or R-dihydrolipoic acid, acetyl-1-carnitine, and 1-carnosine.

The invention encompasses compositions and methods for treating or preventing disorders in companion animals, wherein the compositions and methods include feeding the companion animal a composition including lipoic acid or a salt thereof.

The invention relates to an andrographolide derivative, which has the structure as shown in a general formula I: wherein, R1, R2 and R3 are the same or different hydrogen, substituted or non-substituted organic acid radical, inorganic acid radical, alkyl, aryl or heteroaryl, while at least one of R1, R2 and R3 is R-lipoic acid or S-lipoic acid or the mixture of R-lipoic acid and S-lipoic acid or the corresponding dihydrolipoic acid or acetylcysteine radical of R-lipoic acid or S-lipoic acid; the derivative has good anti-tumor effect, and the derivative can cause apoptosis of tumor cells, directly eliminate gram positive bacteria, staphylococcus aureus and sensitivities MRSA5676 and MRSA5677, inhibit the QS system of gram negative bacteria and pseudomonas aeruginosa and inhibit and damage the formation of the bio-film of pseudomonas aeruginosa; the product has prominent hypoplycemic effect and is suitable for the preparation of the medicines that can cure cancers, inflammations, diabetes mellitus and bacterial and viral infection.

A method of stabilizing R-α-lipoic acid includes combining R-α-lipoic acid with nicotinamide in a weight ratio between about 10:4 to about 10:8. A composition for treating oxidative stress includes R-α-lipoic acid and nicotinamide in a weight ratio of between about 10:4 and about 10:8.

Embodiments include a composition to promote ocular health and a method of treatment for a subject exposed to a source of oxidative or visual stress to the eye or having a degradation of the eye. The composition may include amounts of vitamin A, which includes beta-carotene; vitamin C; vitamin D; vitamin E; zinc; copper; selenium; non-vitamin A carotenoids, which include lutein and zeaxanthin; omega-3 fatty acids, which include eicosapentaenoic acid and docosahexaenoic acid; taurine; alpha lipoic acid; pine bark extract; astaxanthin; and Piper spp. extract. The method includes the step of administering to the subject a daily dose of a composition to promote ocular health.

The present invention relates to compositions without added iron and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the method involves administering to an individual a composition comprising carotenoids, vitamin E, vitamin D, vitamin C, thiamine, riboflavin, niacin, folic acid, pyridoxine, biotin, pantothenic acid, cobalamin, magnesium, manganese, zinc, selenium, chromium, copper, alpha lipoic acid, and lutein, wherein the composition is free of added iron.

The present invention concerns the use of Provided is a drug composition and a method for using the composition for the prevention and the therapy of neurodegenerative diseases. The combination comprises at least two of the following substances: α-lipoic acid; ambroxol and one or several inhibitor(s) of the angiotension-converting enzyme (ACE).

The present invention relates to compositions and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the composition provides a nutritional supplement with a beneficial increased supplementation of vitamin D and the method involves administering to an individual a composition comprising carotenoids, vitamin E, vitamin D, vitamin C, thiamine, riboflavin, niacin, folic acid, pyridoxine, biotin, pantothenic acid, cobalamin, magnesium, manganese, zinc, selenium, chromium, copper, alpha lipoic acid, and lutein.

The invention relates to the field of medical technologies, in particular to a lipoic-acid-modified nanometer polypeptide carrier and a preparation method and application thereof.The lipoic-acid-modified nanometer polypeptide carrier is composed of arginine, histidine, lipoic acid and cysteine.A disulfide bond contained in lipoic acid is adopted for cross-linking, a formed polypeptide polymer can be rapidly degraded in cells and will not accumulate in the cells, and arginine and cysteine in polypeptide are in-vivo amino acid and are free of toxic and side effects to the human body.A CCK-8 cell proliferation test shows that the prepared nanometer carrier has low cell toxicity and meanwhile has good capacity of co-delivery of a gene and chemotherapy drugs; the nanometer carrier can specifically enhance the sensitivity of drug-resistant cells to the chemotherapy drugs in breast cancer drug-resistant treatment and promote apoptosis of breast cancer cells, and therefore becomes a targeted, efficient and low-toxicity nanoscale delivery system in breast cancer drug-resistant treatment.

The invention provides preserving fluid of hepatic cells for a biological artificial liver and a preparation method thereof. The preserving fluid is a solution compounded by ultrapure water. The solution contains the following components within the concentration range: 15-25mmol/L of disodium hydrogen phosphate, 1-10mmol/L of sodium hydrogen phosphate dehydrate, 4-6mmol/L of potassium citrate monohydrate, 10-30mmol/L of sodium chloride, 5-10mmol/L of magnesium chloride hexahydrate, 3-10mmol/L of disodium adenosine triphosphate, 1-5mmol/L of reducing glutathione, 0.1-0.5mmol/L of alpha-lipoic acid, 100-150mmol/L of trehalose (C6H12O5), 200/0.510-50g/L of hydroxyethyl starch and 2-10mg/L of matrine. The preparation method of the preserving fluid comprises the following steps of: accurately weighing all components according to the concentration requirements of the components, wherein the alpha-lipoic acid is weighed in a dark place; completely dissolving the other components except the alpha-lipoic acid by using the right amount of ultrapure water; sufficiently dissolving the alpha-lipoic acid in the dark place; and adding the ultrapure water to full dose. The preserving fluid can well protect the cell activity of the hepatic cells for the biological artificial liver and the special functions of the hepatic cells at low temperature so as to satisfy the short-term low temperature preservation of a large-scale hepatic cell bank for the biological artificial liver and/or the hepatic cell protection in the long-distance transportation process.

A dietary supplemental composition composed of Acetyl-L-Carnitine, Phosphatidylserine, L-Alpha-Glycerylphosphorylcholine, fish oils including Docosahexaenoic acid, Alpha Lipoic Acid, and optionally Eicosapentaenoic acid, and which in combination has been demonstrated to be effective in increasing cognitive performance, elevating mood and decreasing oxidative stress levels in mammals.

The invention relates to a nutrient composition for eliminating exercise-induced fatigue, and discloses a mixture. The mixture comprises R-lipoic acid, acetylcarnitine, biotin, niacinamide, lactoflavin, pyridoxal, kreatine, coenzyme Q10, resveratrol and taurine. The mixture has a good effect on fatigue resistance, and has safe use, small toxic and side effects, stability and controllability.

The invention discloses a lipoic acid composition for injection, which is an injection and comprises the components of lipoic acid, a compatibilizer and an antioxidant. The disclosed lipoic acid composition has high stability by taking methionine as the antioxidant.

The invention discloses a method for preparing an alpha-lipoic acid liposome, which comprises: dissolving soyabean lecithin and cholesterol in an organic solvent and adding the solution into solution of alpha-lipoic acid to form liposome solution, wherein the mass ratio of the soyabean lecithin to the cholesterol to the alpha-lipoic acid is 3.1-3.5:1:0.03-0.06; forming a thin film by water bath treatment, pressure reduction and distillation; and adding an ethylether assistant and forming the homogeneous liposome by hydration and crushing. The alpha-lipoic acid liposome preparation by the method is homogeneous, stable and high in entrapment rate and is favorable for industrial production.

The present invention concerns an enantiomer R of a compound of Formula (I), wherein X is —NH—R₁ or of Formula (V) or (VI), R₁ is —(CH₂)_n—R₂, R₂ is a linear, branched or cyclic C₁C₆ aliphatic group, —O—(CH₂)_n—CH₃, —NH—CO—(CH₂)_n—CH₃, a 5- or 6-membered aliphatic or aromatic ring optionally comprising a heteroatom, a 5- or 6-membered aromatic ring substituted by one or two substituents, said substituents being selected from the group consisting of —OH, —O(alkyl C₁C₃) and —OCO(alkyl C₁C₃), or of Formula (V), R₃ is H or a C₁-C₃ aliphatic group and R₄ is a linear C₁-C₃ or a branched C₃-C₁₂ aliphatic group, or R₃ is a C₁-C₃ aliphatic group and R₄ is a linear C₁-C₁₂ aliphatic group, Y is O, CH—(CH₂)_n—CH₃ or N(CO)(CH₂)_n—CH₃, and n is an integer from O to 6. It has been found that the enantiomers of the invention are able to release (R)-alpha-lipoic acid, ensuring a longer permanence in the body for the pharmacologically active principle than that obtainable by its direct administration, or to simulate the pharmacological action of alpha-lipoic acid itself, while exhibiting a much more intense and lasting activity.

A stabilized dihydrolipoic acid (DHLA) compound is provided. The stabilized DHLA is derived from a microbiological culture media including at least one live probiotic organism, R-lipoic acid and at least one nutritive agent. The stabilized DHLA may be prepared by dispersing the microbiological media in distilled water to form a broth, incubating the broth at a predetermined temperature for a select period of time to induce probiotic activity, adding organic ethanol to the broth to halt the probiotic activity, and separating the derived stabilized DHLA from the broth.

The present invention provides a lipoic acid injection liquid and a preparation method thereof, the preparation method comprises the following steps: (1) first a co-solvent is dissolved in part of water for injection, and lipoic acid is added and dissolved; (2) a solution obtained by the step (1) is ultrafiltered for removal of pyrogen; (3) water for injection is added into a solution obtained by the step (2) for volume fixing to a final volume, the solution is evenly mixed and then filtered, and an inert gas is introduced to remove oxygen; and (4) under inert gas protection, the lipoic acid injection liquid is filled and sterilized. The preparation method does not take any antioxidant, the content of oxidation products formed by degradation of lipoic acid still can be effectively controlled, and the product quality is, more stable.

The invention encompasses pet food compositions and methods for the treatment and/or prevention of diseases or disorders in companion animals, for example, for the treatment or obesity, including administering a pet food composition including pyruvic acid or a salt thereof to a companion animal, or lipoic acid or salt thereof and pyruvic acid or a salt thereof to a companion animal. The invention encompasses pet food compositions and methods for managing weight including administering a pet food composition including pyruvic acid or a salt thereof, or lipoic acid or a salt thereof and pyruvic acid or a salt thereof to a companion animal to a companion animal.

The invention discloses an andrographolidume composition and application thereof. The composition consists of a component I and a component II according to a molar ratio of between 1:10 and 10:1, wherein the component I is at least one of andrographolidume, andrographolidume derivatives and pharmaceutically acceptable salts of the andrographolidume derivatives, and the component II is at least one of lipoic acid and dihydrolipoic acid. The composition can be prepared into anticancer, anti-inflammatory, antibacterial, antivirus or hypoglycemic medicaments.

The invention discloses a racemization method of S-(-)-lipoic acid, the S-(-)-lipoic acid is dissolved in a solvent, heated at 110-220 DEG C under a normal pressure for backflow for at least 15 hours; after the solvent is concentrated, racemization lipoic acid is obtained by crystallization; and the prepared racemization lipoic acid is +/-1 degrees. The invention further relates to a preparing method of R-(+)-lipoic acid, which is characterized in that: using the racemization lipoic acid as raw material; using R-(+)-phenylethy lamine to split enantiomer; racemizing the split S-(-)-lipoic acidas raw material for reuse. The method disclosed by the invention racemizes the S-(-)-lipoic acid, and improves the preparing method of the R-(+)-lipoic acid by a racemization method, so that technology is simplified, yield is obviously increased and production cost is reduced; the racemization method of the S-lipoic acid and the preparing method of the R-lipoic acid have excellent industrial application value.